Share：
Share this content in WeChat
X
[Chinese][PDF]2872
• Clinical Article •
Application of ADC values to assess inflammatory lymph nodes in the drainage area of the salivary glands of patients with primary Sjogren's syndrome
TIAN Manting  DING Changwei 

Cite this article as TIAN M T, DING C W. Application of ADC values to assess inflammatory lymph nodes in the drainage area of the salivary glands of patients with primary Sjogren's syndrome[J]. Chin J Magn Reson Imaging, 2024, 15(5): 68-74. DOI:10.12015/issn.1674-8034.2024.05.012.


[Abstract] Objective To investigate the apparent diffusion coefficient (ADC) and morphology of lymph nodes in the drainage area of salivary glands among patients with primary Sjögren's syndrome (pSS) before and after treatment and healthy volunteer, and its potential in reflecting the degree of inflammatory activity of the disease in patients with pSS.Materials and Methods A total of 23 patients with pSS were collected to undergo routine head and neck MRI and diffusion weighted imaging (DWI) before and after 12 weeks of regular treatment, respectively. ADC images were obtained after post-processing. Then 15 healthy volunteers were collected as controls during the same period. Using t-test to compare the morphology and ADC values of the lymph nodes in each level among the pSS patients before and after treatment, and healthy volunteers.Results The short diameters of lymph nodes in level Ⅰb, Ⅱa, and Ⅱb in patients with pSS before treatment were larger than those of healthy volunteers [Ⅰb (t=2.293, P=0.028), Ⅱa (t=2.397, P=0.022), Ⅱb (t=1.409, P=0.030)] , and the short diameters of lymph nodes in all salivary gland drainage levels were smaller after 12 weeks of treatment [Ⅰa (t=4.391, P<0.001), Ⅰb (t=3.439, P=0.002), Ⅱa (t=3.458, P=0.002), Ⅱb (t=4.667, P=0.001)]. ADC values of lymph nodes in level Ⅰb and Ⅱa in pSS patients before treatment were smaller than those of healthy volunteers [Ⅰb (t=3.337, P=0.002), Ⅱa (t=2.207, P=0.038)] , and they became larger than those of lymph nodes in level Ⅰa, Ⅰb, and Ⅱa after 12 weeks of treatment [Ⅰa (t=3.674, P=0.001), Ⅰb (t=2.198, P=0.039), Ⅱa (t=2.484, P=0.004)].Conclusions The short diameters of lymph nodes in level Ⅰb, Ⅱa and Ⅱb may be of great value in identifying patients with pSS and healthy volunteers, and the short diameters of lymph nodes in all levels may be of great value in identifying patients with pSS before and after treatment; the ADC values of lymph nodes in level Ⅰb and Ⅱa may be of great value in identifying patients with pSS and healthy volunteers, and the ADC values of lymph nodes in level Ia, Ⅰb and Ⅱa may be of great value in identifying patients with pSS before and after treatment.
[Keywords] autoimmune disease；primary Sjögren's syndrome；inflammatory activity of the disease；diffusion weighted imaging；apparent diffusion coefficient；magnetic resonance imaging

TIAN Manting   DING Changwei*  

Department of Radiology, Shengjing Hospital of China Medical University, Shenyang 110004, China

Corresponding author: DING C W, E-mail: 18940254003@163.com

Conflicts of interest   None.

Received  2024-01-06
Accepted  2024-04-23
DOI: 10.12015/issn.1674-8034.2024.05.012
Cite this article as TIAN M T, DING C W. Application of ADC values to assess inflammatory lymph nodes in the drainage area of the salivary glands of patients with primary Sjogren's syndrome[J]. Chin J Magn Reson Imaging, 2024, 15(5): 68-74. DOI:10.12015/issn.1674-8034.2024.05.012.

[1]
SHIBOSKI C H, SHIBOSKI S C, SEROR R, et al. 2016 American college of rheumatology/european league against rheumatism classification criteria for primary sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts[J]. Arthritis Rheumatol, 2017, 69(1): 35-45. DOI: 10.1002/art.39859.
[2]
ANDRÉ F, BÖCKLE B C. Sjögren's syndrome[J]. J Dtsch Dermatol Ges, 2022, 20(7): 980-1002. DOI: 10.1111/ddg.14823.
[3]
YURA Y, HAMADA M. Outline of salivary gland pathogenesis of Sjögren's syndrome and current therapeutic approaches[J/OL]. Int J Mol Sci, 2023, 24(13): 11179 [2024-01-05]. https://pubmed.ncbi.nlm.nih.gov/37446355/. DOI: 10.3390/ijms241311179.
[4]
VITALI C, BOMBARDIERI S, JONSSON R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group[J]. Ann Rheum Dis, 2002, 61(6): 554-558. DOI: 10.1136/ard.61.6.554.
[5]
HOU L, WANG N N, ZHAO C G, et al. A single-center study of clinical features of pediatric Sjögren's syndrome[J]. Pediatr Rheumatol Online J, 2023, 21(1): 119. DOI: 10.1186/s12969-023-00902-y.
[6]
RAMOS-CASALS M, ACAR-DENIZLI N, VISSINK A, et al. Childhood-onset of primary Sjögren's syndrome: phenotypic characterization at diagnosis of 158 children[J]. Rheumatology, 2021, 60(10): 4558-4567. DOI: 10.1093/rheumatology/keab032.
[7]
FLORES-CHÁVEZ A, KOSTOV B, SOLANS R, et al. Severe, life-threatening phenotype of primary Sjögren's syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry)[J]. Clin Exp Rheumatol, 2018, 112(3): 121-129.
[8]
YOKOSAWA M, TSUBOI H, NASU K, et al. Usefulness of MR imaging of the parotid glands in patients with secondary Sjögren's syndrome associated with rheumatoid arthritis[J]. Mod Rheumatol, 2015, 25(3): 415-420. DOI: 10.3109/14397595.2014.958892.
[9]
VAN GINKEL M S, GLAUDEMANS A W J M, VAN DER VEGT B, et al. Imaging in primary Sjögren's syndrome[J/OL]. J Clin Med, 2020, 9(8): 2492 [2024-01-05]. https://pubmed.ncbi.nlm.nih.gov/32756395/. DOI: 10.3390/jcm9082492.
[10]
TAKAGI Y, SASAKI M, EIDA S, et al. Comparison of salivary gland MRI and ultrasonography findings among patients with Sjögren's syndrome over a wide age range[J]. Rheumatology, 2022, 61(5): 1986-1996. DOI: 10.1093/rheumatology/keab560.
[11]
IZUMI M, EGUCHI K, OHKI M, et al. MR imaging of the parotid gland in Sjögren's syndrome: a proposal for new diagnostic criteria[J]. AJR Am J Roentgenol, 1996, 166(6): 1483-1487. DOI: 10.2214/ajr.166.6.8633469.
[12]
CHOI S S, JANG E, OH Y K, et al. Aged sanroque mice spontaneously develop Sjögren's syndrome-like disease[J/OL]. Immune Netw, 2019, 19(1): e7 [2024-01-05]. https://pubmed.ncbi.nlm.nih.gov/30838162/. DOI: 10.4110/in.2019.19.e7.
[13]
THOENY H C, KEYZER F D, CLAUS F G, et al. Gustatory stimulation changes the apparent diffusion coefficient of salivary glands: initial experience[J]. Radiology, 2005, 235(2): 629-634. DOI: 10.1148/radiol.2352040127.
[14]
CHAVHAN G B, ALSABBAN Z, BABYN P S. Diffusion-weighted imaging in pediatric body MR imaging: principles, technique, and emerging applications[J/OL]. Radiographics, 2014, 34(3): E73-E88 [2024-01-05]. https://pubmed.ncbi.nlm.nih.gov/24819803/. DOI: 10.1148/rg.343135047.
[15]
OBARA M, KWON J, YONEYAMA M, et al. Technical advancements in abdominal diffusion-weighted imaging[J]. Magn Reson Med Sci, 2023, 22(2): 191-208. DOI: 10.2463/mrms.rev.2022-0107.
[16]
CHU C, WANG F X, ZHANG H Y, et al. Whole-volume ADC histogram and texture analyses of parotid glands as an image biomarker in evaluating disease activity of primary Sjögren's syndrome[J/OL]. Sci Rep, 2018, 8(1): 15387[2024-01-05]. https://pubmed.ncbi.nlm.nih.gov/30337659/. DOI: 10.1038/s41598-018-33797-x.
[17]
SEROR R, RAVAUD P, BOWMAN S J, et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome[J]. Ann Rheum Dis, 2010, 69(6): 1103-1109. DOI: 10.1136/ard.2009.110619.
[18]
SEROR R, BOOTSMA H, SARAUX A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)[J]. Ann Rheum Dis, 2016, 75(2): 382-389. DOI: 10.1136/annrheumdis-2014-206008.
[19]
PONTARINI E, LUCCHESI D, BOMBARDIERI M. Current views on the pathogenesis of Sjögren's syndrome[J]. Curr Opin Rheumatol, 2018, 30(2): 215-221. DOI: 10.1097/BOR.0000000000000473.
[20]
FRAGKIOUDAKI S, MAVRAGANI C P, MOUTSOPOULOS H M. Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use[J/OL]. Medicine, 2016, 95(25): e3766 [2024-01-05]. https://pubmed.ncbi.nlm.nih.gov/27336863/. DOI: 10.1097/MD.0000000000003766.
[21]
GRÉGOIRE V, ANG K, BUDACH W, et al. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines[J]. Radiother Oncol, 2014, 110(1): 172-181. DOI: 10.1016/j.radonc.2013.10.010.
[22]
GADDEY H L, RIEGEL A M. Unexplained lymphadenopathy: evaluation and differential diagnosis[J]. Am Fam Physician, 2016, 94(11): 896-903.
[23]
LIANG H Y, XING J, HAO H, et al. Study on the evaluation of breast cancer axillary lymph node status with magnetic resonance imaging[J]. J Clin Radiol, 2022, 41(7): 1292-1297. DOI: 10.13437/j.cnki.jcr.2022.07.032.
[24]
BOIS H D, HEIM T A, LUND A W. Tumor-draining lymph nodes: At the crossroads of metastasis and immunity[J/OL]. Sci Immunol, 2021, 6(63): eabg3551 [2024-01-05]. https://pubmed.ncbi.nlm.nih.gov/34516744/. DOI: 10.1126/sciimmunol.abg3551.
[25]
GULLO R L, PARTRIDGE S C, SHIN H J, et al. Update on DWI for breast cancer diagnosis and treatment monitoring[J/OL]. AJR Am J Roentgenol, 2024, 222(1): e2329933 [2024-01-05]. https://pubmed.ncbi.nlm.nih.gov/37850579/. DOI: 10.2214/AJR.23.29933.
[26]
HUANG S L, WU M X, ZENG X B, et al. Effect of dynamic contrast-enhanced MRI combined with DWI in the diagnosis of endometrial carcinoma and its correlation with COX-2 expression[J]. J China Clin Med Imag, 2020, 31(4): 293-295. DOI: 10.12117/jccmi.2020.04.015.
[27]
GUO J, WANG J P, LI W. Diffusion-weighted imaging in qualitative diagnosis of pelvic lymph nodes in patients with endometrial cancer[J]. Chin J Med Imag, 2013, 21(3): 227-230. DOI: 10.3969/j.issn.1005-5185.2013.03.020.
[28]
DING C W, XING X F, GUO Q Y, et al. Diffusion-weighted MRI findings in Sjögren's syndrome: a preliminary study[J]. Acta Radiol, 2016, 57(6): 691-700. DOI: 10.1177/0284185115603245.
[29]
DU J J, DONG X H, GAO J, et al. Correlations between anti-SSB and other laboratory parameters in patients with primary Sjogren's syndrome[J]. Lab Med Clin, 2023, 20(16): 2395-2399. DOI: 10.3969/j.issn.1672-9455.2023.16.021.
[30]
PU J C, WANG X, RIAZ F, et al. Effectiveness and safety of iguratimod in treating primary Sjögren's syndrome: a systematic review and meta-analysis[J/OL]. Front Pharmacol, 2021, 12: 621208 [2024-01-05]. https://pubmed.ncbi.nlm.nih.gov/33815105/. DOI: 10.3389/fphar.2021.621208.
[31]
ZENG L T, HE Q, YANG K L, et al. A systematic review and meta-analysis of 19 randomized controlled trials of iguratimod combined with other therapies for Sjogren's syndrome[J/OL]. Front Immunol, 2022, 13: 924730 [2024-01-05]. https://pubmed.ncbi.nlm.nih.gov/35967307/. DOI: 10.3389/fimmu.2022.924730.
[32]
KALLENBERG C G M, VISSINK A, KROESE F G M, et al. What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?[J/OL]. Arthritis Res Ther, 2011, 13(1): 205 [2024-01-05]. https://pubmed.ncbi.nlm.nih.gov/21371351/. DOI: 10.1186/ar3234.
[33]
MAŚLIŃSKA M, MAŃCZAK M, KWIATKOWSKA B. Usefulness of rheumatoid factor as an immunological and prognostic marker in PSS patients[J]. Clin Rheumatol, 2019, 38(5): 1301-1307. DOI: 10.1007/s10067-019-04438-z.
[34]
SEROR R, SORDET C, GUILLEVIN L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome[J]. Ann Rheum Dis, 2007, 66(3): 351-357. DOI: 10.1136/ard.2006.057919.
[35]
VÍLCHEZ-OYA F, BALASTEGUI MARTIN H, GARCÍA-MARTÍNEZ E, et al. Not all autoantibodies are clinically relevant. Classic and novel autoantibodies in Sjögren's syndrome: a critical review[J/OL]. Front Immunol, 2022, 13: 1003054 [2024-01-05]. https://pubmed.ncbi.nlm.nih.gov/36325321/. DOI: 10.3389/fimmu.2022.1003054.
[36]
SHAO Q, WANG S, JIANG H, et al. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial[J]. Scand J Rheumatol, 2021, 50(2): 143-152. DOI: 10.1080/03009742.2020.1809701.

PREV Diagnostic value of quantitative measurement of orbital structure by 3 T MRI in staging of Graves ophthalmopathy
NEXT Preliminary study on MRI features of the lower lip salivary glands in Sjögren,s syndrome
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn